How We’ve Been Cashing In On The GLP-1 Craze
The booming market for weight-loss drugs, particularly GLP-1 agonists, have led to substantial gains in drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY). The latter is seeing its share price approach the $1,000 level, putting it out of reach for most investors.
But we’ve been able to generate thousands of dollars from LLY over the past year and boost our rates of return using a simple options-selling strategy.
